A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension

This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

Inclusion Criteria:

• Diagnosis of hypertension with blood pressure ≥ 140/90 millimeters of mercury (mmHg) and < 180/110 mmHg on current antihypertensive treatment
• Male and female participants 18-75 years of age
• Participants must weigh at least 50 kilograms (kg)

Exclusion Criteria:

• Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or transient ischemic attack
• Clinically significant electrocardiography (ECG) findings related to cardiac conduction defects
• Type 1 diabetes or uncontrolled type 2 diabetes (haemoglobin A1c [HbA1c] > 9%)
• Malignancies within the last 5 years (excluding basal cell skin cancer)
• Liver disease

Other protocol-defined inclusion/exclusion criteria may apply.